Chembio Launches U.S. Sales of its SURE CHECK® HIV 1/2

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Chembio Launches U.S. Sales of its SURE CHECK® HIV 1/2 Assay and Reduces Prices of HIV Tests for U.S. Public Health Market

MEDFORD, N.Y., June 01, 2016 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI ), a leader in point-of-care (POC) diagnostic tests for infectious diseases, today announced the launch of U.S. sales of its Chembio-branded SURE CHECK ® HIV 1/2 Assay.  In connection with this launch, the Company is implementing a new pricing strategy for its POC HIV products for the U.S. public health market with the goal of increasing testing frequency and reducing rates of HIV infection.  Effective immediately, the Company will begin selling its HIV tests in the U.S. public health market at a price of five dollars ($5.00) per test, which represents a significant discount from current pricing.

Products to be offered under this new pricing initiative include Chembio’s three FDA-approved, CLIA-Waived HIV assays (DPP ® HIV 1/2, SURE CHECK ® HIV 1/2, and HIV 1/2 STAT-PAK ® ).  This product portfolio provides customers with multiple POC HIV testing options, as well as the ability to use either fingerstick or venous whole blood or oral fluid samples.  The Company’s SURE CHECK ® HIV 1/2 Assay was previously sold in the U.S. as Clearview ® COMPLETE HIV 1/2 Assay. Beginning today, the easy-to-use POC HIV test will be marketed under Chembio’s brand name, SURE CHECK ® HIV 1/2 Assay.

The Centers for Disease Control and Prevention (CDC) estimates that approximately 1.2 million people are living with HIV infection in the U.S., including approximately 156,000 (12.8%) who are unaware of their positive HIV status. Over the past decade, the number of people living with HIV infection in the U.S. has increased, while the annual number of new HIV infections has remained relatively stable at approximately 50,000 per year. Still, the pace of new infections continues at far too high a level.

John Sperzel, Chembio's Chief Executive Officer, commented, “According to the CDC, there are approximately 50,000 new HIV infections annually in the U.S., a number that has not declined despite the availability of numerous laboratory and POC tests to detect HIV antibodies or antigens. Building on the foundation of the CDC’s three-year HIV Expanded Testing Initiative, and supporting the 2015-2020 National HIV/AIDS Strategy, which includes ‘widespread testing and linkage to care’ as one of the four key areas of critical focus, our newly-launched price reduction in the U.S. public health market seeks to facilitate increased POC HIV testing with Chembio’s high-quality HIV assays, demonstrating our corporate commitment to reduce the number of annual HIV infections in the U.S.”

Mr. Sperzel further commented, “Historically, Chembio’s U.S. sales and marketing efforts for SURE CHECK ® HIV 1/2 and HIV 1/2 STAT-PAK ® Assays were controlled by an exclusive marketing partner.  This relationship ended for our HIV 1/2 STAT-PAK ® Assay in 2014 and for our SURE CHECK ® HIV 1/2 Assay on May 31, 2016. To mark the beginning of a new era, Chembio has announced a major price reduction in the U.S. public health market.

“Our POC HIV assays are effective in identifying HIV infections, including early detection. According to a CDC evaluation of HIV assays, Chembio’s DPP ® HIV 1/2,  SURE CHECK ® HIV 1/2, and HIV 1/2 STAT-PAK ® Assays all identified infections earlier than OraQuick ADVANCE ® HIV 1/2 (OraSure Technologies, Inc.) and Uni-Gold ™ Recombigen ® HIV 1/2 (Trinity Biotech plc). 1 By selling our high-quality HIV assays in the U.S. public health market at five dollars ($5.00) per test, we believe we can play a role in reducing the number of annual HIV infections in the U.S. through increased POC testing.”

1 http://www.cdc.gov/hiv/pdf/testing_Advantages...ntages.pdf

About Chembio Diagnostics

Chembio Diagnostics, Inc. develops, manufactures, licenses and markets proprietary rapid diagnostic tests in the growing $8.0 billion point-of-care testing market. Chembio markets its DPP ® HIV 1/2 Assay, HIV 1/2 STAT-PAK ® Assay and SURE CHECK ® HIV 1/2 Assay, with these Chembio brand names, in the U.S. and internationally both directly and through third-party distributors. SURE-CHECK ® HIV 1/2 Assay previously has been sold in the U.S. exclusively as Clearview ® COMPLETE HIV 1/2 Assay.

Chembio has developed a patented point-of-care test platform technology, the Dual Path Platform (DPP ® ) technology, which has significant advantages over lateral-flow technologies. This technology is providing Chembio with a significant pipeline of business opportunities for the development and manufacture of new products.

Headquartered in Medford, NY, Chembio is licensed by the U.S. Food and Drug Administration (FDA) as well as the U.S. Department of Agriculture (USDA), and is certified for the global market under the International Standards Organization (ISO) directive 13485. Chembio Diagnostic Systems, Inc. is a wholly-owned subsidiary of Chembio Diagnostics, Inc. For more information, please visit: www.chembio.com .

Forward-Looking Statements

Statements contained herein that are not historical facts may be forward-looking statements within the meaning of the Securities Act of 1933, as amended. Forward-looking statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements, which are estimates only, reflect management's current views, are based on certain assumptions, and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to Chembio's ability to obtain additional financing and to obtain regulatory approvals in a timely manner, as well as the demand for Chembio's products. Chembio undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in Chembio's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact Chembio's success are more fully disclosed in Chembio's most recent public filings with the U.S. Securities and Exchange Commission.

CONTACT: Contacts: Chembio Diagnostics Susan Norcott (631) 924-1135, ext. 125 snorcott@chembio.com Vida Strategic Partners (investor relations) Stephanie C. Diaz (415) 675-7401 sdiaz@vidasp.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Mace Consult Bets on Sawaya for Americas Expansion

Updated Category News Views 15

Concrete, tunnel bores, and data-center campuses rarely wait politely for a leadership transition. Mace Consult has named Mario Sawaya president of its Americas business, and the hire reads less like ceremonial executive shuffling than a deliberate move toward the thickest part of the capital-spending map. Sawaya brings more than 20 years of experience leading...

Continue Reading
Star Catcher Powers a Public-Interest Space Bet Ahead

Updated Category News Views 94

A satellite’s battery budget is a rotten place for humanitarian priorities to die. Common Space and Star Catcher are trying to remove that bottleneck through a partnership that is easy to like on principle and still deserves a clear-eyed look on execution. Common Space, a nonprofit developing an independent, community-governed high-resolution satellite constellation,...

Continue Reading
Travelzoo Turns Thanksgiving Delays Into Member Value

Updated Category News Views 108

Airport gridlock is a miserable place to make a membership pitch, yet Travelzoo has found a pretty shrewd angle for it. On November 18, the company said nearly 20 million travelers will move through airports during the upcoming Thanksgiving holiday, when cancellations and delays can turn an ordinary trip into a long, fluorescent-lit slog. Its offer: qualifying Club...

Continue Reading
JOYY’s Ad Engine Gives Q3 Growth Some Real Teeth Now

Updated Category News Views 107

Three engines are finally pulling the cart at JOYY, and that is a far more interesting sight than another quarter of livestreaming merely holding together. The company reported third-quarter 2026 revenue of US$624.6 million, up 15.6% from a year earlier and 5.7% sequentially. Those are sturdy numbers, especially for a business that investors have long tended to box in as...

Continue Reading
BLLN Faces Fresh Questions After Short-Seller Report

Updated Category News Views 106

A six-percent air pocket is one thing; a disclosure mismatch is another beast entirely. BillionToOne shares fell on November 18 after short-seller Fuzzy Panda Research alleged the company had not disclosed meaningful regulatory scrutiny, including an alleged Tennessee matter in which regulators suspected fraud in 2024. That is an allegation from a short seller, not a...

Continue Reading
Hyster-Yale’s $135 Million Convert Carries Real Cost

Updated Category News Views 82

Forklift makers do not usually get to hide a 7.50% borrowing cost behind glossy financing jargon. Hyster-Yale has priced $135 million of convertible senior notes due in 2031, lifting the deal from the originally announced $125 million. There is also an option for initial purchasers to take another $20 million. For NYSE:HY shareholders, this is not a simple debt cleanup....

Continue Reading
LiberNovo's European Black Friday Sale Tests Demand

Updated Category News Views 139

A €1,339 chair has no business pretending it is an impulse buy, which is exactly why LiberNovo’s Black Friday push deserves a closer look. The Hong Kong-based ergonomic-chair seller has rolled out its Black Friday sale across the European Union and United Kingdom, with the campaign ending November 30 at 23:59 CET in the EU and 23:59 GMT in the UK. This is a...

Continue Reading
Implantica's U.S. Launch Arrives With Cash Still to Burn

Updated Category News Views 77

RefluxStop has finally stepped onto American soil, and that changes the conversation around Implantica in a very real way. FDA Premarket Approval arrived on August 20, then the first U.S. procedures were completed in early November at the University of Southern California. For a small medtech outfit, clearing that regulatory gate and getting actual patients treated are...

Continue Reading
Honda Prelude’s Hybrid Return Tests a Narrow Niche

Updated Category News Views 0

A low-slung coupe showing up in Newfoundland is not exactly a volume-sales thunderclap, and that is precisely why the 2027 Honda Prelude deserves a closer look. Steele Honda in St. John’s is presenting the hybrid two-door as a fresh choice for buyers who want something livelier than the usual practical commuter. For Honda, and for investors watching Honda Motor Co....

Continue Reading
Whole-House Remodels Need a Plan Before Any Finishes

Updated Category News Views 98

A remodel gets expensive the minute somebody falls in love with tile before checking what sits behind the wall. Adam Sherman’s central point in the HelloNation article is refreshingly unglamorous: treat the house as one working system before treating it as a collection of rooms crying out for cosmetic rescue. That sounds obvious until you see how often a kitchen...

Continue Reading

Top 5 Most Recently Viewed Articles

Amazon.com: A Detailed Look at Its Sway in Retail Markets

Updated Category News Views 265

Understanding Amazon.com and Its Competitive Landscape In an ever-changing and highly competitive retail space, analyzing key players is vital for investors and industry experts. This article aims to provide an in-depth evaluation of Amazon.com (NASDAQ: AMZN), delving into its performance compared to major competitors in the broadline retail sector. By thoroughly...

Continue Reading
Navigating the AI Landscape: Nvidia and the Future of Technology

Updated Category News Views 210

Nvidia: The Titan Amid the AI Hype Nvidia (NASDAQ: NVDA) has become a central figure in the tech world, particularly in the booming AI sector. However, some critics argue that the excitement surrounding AI is overshadowing the realistic capabilities of the technology. The true concern lies not with Nvidia, which is currently dealing with constraints in compute resources,...

Continue Reading
Market Insights on Automatic Data Processing's Short Interest

Updated Category News Views 150

Understanding Short Interest in Automatic Data Processing Automatic Data Processing's (ADP) short percent of float has recently dipped by 3.97% compared to its previous report. Currently, the company has reported approximately 4.93 million shares sold short, representing 1.21% of its available trading shares. Based on the current trading activity, it would take traders...

Continue Reading
Thesis Gold Inc. Unveils Compelling Drilling Results for Bingo

Updated Category News Views 159

Thesis Gold Inc. Reports Exciting Drilling Results at Bingo Zone Thesis Gold Inc. (TSXV: TAU) has recently revealed outstanding drilling outcomes from its Bingo Zone, marking a pivotal moment in the company’s ongoing exploration at its wholly-owned Lawyers-Ranch Project. This project is nestled within a highly regarded mining region, and the recent discoveries promise...

Continue Reading
October Distributions Announced by Roundhill Investments ETFs

Updated Category News Views 52

Roundhill Investments Announces ETF Distributions Roundhill Investments, a leading ETF sponsor known for its innovative financial products, recently announced the distributions for several of its exchange-traded funds (ETFs) including XDTE, QDTE, and RDTE, effective this October. This news is particularly relevant for investors looking to stay informed about their...

Continue Reading